ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,049.88
0.05%
US Tech 100
20,674.80
0.00%
Dow Jones
44,705.53
-0.17%
Brent Oil
73.69
0.12%
Bitcoin
96,691.00
0.75%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Invivyd Inc (IVVD) Quote

Invivyd Inc

Invivyd Inc (IVVD)

NASDAQ
0.6414
0.00
(0.00%)
Closed December 04 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.6414
Bid
0.6414
Ask
0.6648
Volume
-
0.00 Day's Range 0.00
0.58 52 Week Range 5.195
Market Cap
76.722M
Previous Close
0.6414
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
525,240
Shares Outstanding
119,616,035
Dividend Yield
-
PE Ratio
-2.79
Earnings Per Share (EPS)
-1.66
Revenue
-
Net Profit
-198.64M

About Invivyd Inc

Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
invivyd.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Invivyd Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IVVD. The last closing price for Invivyd was $0.64. Over the last year, Invivyd shares have traded in a share price range of $ 0.58 to $ 5.195.

Invivyd currently has 119,616,035 shares outstanding. The market capitalization of Invivyd is $76.72 million. Invivyd has a price to earnings ratio (PE ratio) of -2.79.

Ask ADVFN Intelligence (AI)

IVVD Latest News

More News

Form 8-K - Current report

December 02 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 14 2024
Edgar (US Regulatory)

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing...

November 14 2024
GlobeNewswire Inc.

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provides an updated correlate of protection curve...

November 14 2024
GlobeNewswire Inc.

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort B during KP.3 and KP.3.1.1...

November 12 2024
GlobeNewswire Inc.

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today...

November 06 2024
GlobeNewswire Inc.

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today...

November 06 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 29 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01642.6240.6250.78180.623510283300.67762905CS
4-0.348499-35.20551086520.9898991.070.587929970.75887682CS
12-0.2539-28.35920920360.89531.270.585252400.89575742CS
26-1.1786-64.75824175821.821.890.585557391.02865378CS
52-0.8686-57.52317880791.515.1950.589042382.79091555CS
156-4.0586-86.35319148944.75.1950.585569982.56333823CS
260-4.0586-86.35319148944.75.1950.585569982.56333823CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 14.47
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 69.03
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.48
(0.00%)
0
AACGATA Creativity Global
$ 0.9752
(0.00%)
0
AALAmerican Airlines Group Inc
$ 14.47
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 69.03
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.48
(0.00%)
0
AACGATA Creativity Global
$ 0.9752
(0.00%)
0
AALAmerican Airlines Group Inc
$ 14.47
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 69.03
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.48
(0.00%)
0
AACGATA Creativity Global
$ 0.9752
(0.00%)
0

IVVD Discussion

View Posts
Monksdream Monksdream 3 months ago
IVVD new 52 low

👍️0
Monksdream Monksdream 3 months ago
IVVD new 52. Low
👍️0
Monksdream Monksdream 4 months ago
IVVD new 52 low
👍️0
Monksdream Monksdream 4 months ago
IVVD new 52 week low
👍️0
Monksdream Monksdream 4 months ago
IVVD under $2
👍️0
Monksdream Monksdream 4 months ago
IVVD under $2
👍️0
Monksdream Monksdream 5 months ago
IVVD under $2
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
WHICH STOCK DO YOU OWN....RSPI OR SMCE
👍️0
Rockstar55 Rockstar55 5 months ago
Technical DUMP coming. Massive dilution
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
IVVD...TECHNICAL BOUNCE COMING IN
👍️0
Monksdream Monksdream 7 months ago
IVVD under $5
👍️0
Invest-in-America Invest-in-America 8 months ago
IVVD: Sounds fine to ME, Boss!!! (Hope you're smokin' a nice 'Rollie' today, behind all those OTHER Pot stocks of late, Dude!!)
👍️0
tw0122 tw0122 8 months ago
Boom time
👍️0
Invest-in-America Invest-in-America 12 months ago
Hey, Boss, and many OTHER basics of LEGITIMATE pharma research reports that were CONSPICUOUSLY MISSING from this scamming Firm's PR.
👍️0
MiamiGent MiamiGent 12 months ago
Interesting to learn this.
👍️0
Invest-in-America Invest-in-America 12 months ago
IVVD: Did anyone else here detect this Firm's CLEVER technique of AVOIDING the deployment of the term "VACCINE" throughout their PR's today??? When in FACT, it is simply yet another form of VACCINE that they are attempting to produce & market. I.e., their PR's were deliberately worded to hopefully impress investors that they might have an actual TREATMENT/THERAPUTIC drug intended to CURE people who have already CONTRACTED whatever forms of COVID. (SCANDALOUS STUFF!!!)
👍️0
MiamiGent MiamiGent 12 months ago
IVVD Quick synopsis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173449647
👍️0
Monksdream Monksdream 1 year ago
IVVD under $2
👍️0
makinezmoney makinezmoney 2 years ago
$IVVD: Presentation at JPMorgan Healthcare Conference today......... now 1.80

She goinggggggggggggggggg

Curl off the bottom


https://investors.invivyd.com/static-files/d49cc2c1-6578-405e-b83c-2ca19ad1a2c9


GO $IVVD
👍️0

Your Recent History

NASDAQ
IVVD
Invivyd
NASDAQ
ITQ
Itiquira Acquisition
NASDAQ
IDEX
Ideanomics
NASDAQ
IDWK
International Displayworks
NASDAQ
IMAN
Imanage
NASDAQ
IACI
NASDAQ
IUSA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved